x
ServiziMenu principaleHome
You are here: Home > Career Development and Opportunities > Certificates of Competence and Advanced Studies > Certificate of Advanced studies in Lung Cancer (CASLu)
Share Print

Certificate of Advanced studies in Lung Cancer (CASLu)

Overview

Collaborating university:  University of Zurich

The Certificate of Advanced Studies in Lung cancer (CASLu) was launched in 2018 and is the first competence programme which focuses on both the clinical and the scientific competence of improving quality in the management of patients with lung cancer and other thoracic malignancies.

This programme, which is offered on a part-time basis over 14 months, is divided into three attendance seminars and four online modules.

Upon successful completion of the programme, participants will obtain an academic certificate issued by the University of Zurich assigning 14 European Credit Transfer and Accumulation System Points (ECTS), equalling a work load of 420 hours, and a diploma supplement by the University of Zurich.

                

Curriculum

Download full CASLu curriculum here

 

Seminar 1 

Module 1 

Module 2

Seminar 2

Module 3

Module 4

Seminar 3

Total 

Timeline

 2021
 24-27 March

2021
Apr/
mid-Jul

2021
mid-Jul/ mid-Oct

2021
17-21 Sept

2021-22
Nov/ Jan 2022

2022
 Jan/mid -April


2022
23-26 May

14 months 

Content

Reading materials (5 hrs)
+
CASLu course (4 hrs)
+
ELCC
(VIRTUAL) (21 hrs)

Epidemiology,
prevention,
biology and
pathology of lung
cancer and
other thoracic malignancies

 Principles of
lung cancer research



Reading materials (5 hrs)
+
CASLu course (2 hrs)
+
Selected sessions
of the ESMO Congress
(VIRTUAL) (23 hrs)

Principles of
NSCLC diagnosis
and treatment

Principles of
treatment
of SCLC, MPM,
thymoma &
thymic cancer

Pre-seminar
preparation of
a clinical case presentation (5 hrs)
+
CASLu course Zurich, CH
including
final exam (25 hrs)

 

Workload

25 hrs
in-person
+ 5 hrs reading
materials

26 units
78 hrs
Distance learning
+ test

24 units
72 hrs
Distance learning
+ test

25 hrs in-person
+ 5 hrs reading materials

30 units
90 hrs
Distance learning
+ test

30 units
90 hrs
Distance learning
+ test

25 hrs
in-person
+ 5 hrs
preparation
of a clinical
case
incl. certificate exam

90 hrs
seminars +
330 hrs
distance l.
420 hrs

Credits

1 ECTS 

5 ECTS

1 ECTS 

3 ECTS

3 ECTS

1 ECTS

14ECTS 

 

Admission and Eligibility

Admission

Admission to the Certificate of Advanced Studies in Lung Cancer is by competitive application only and the selection will be based on the eligibility criteria and on the selection procedure.

Applications will be considered if received completed with all required documents and within the deadline. Attendance is limited to 25 participants.

The following documents are to be included in the application:

Curriculum vitae outlining previous education and professional experience
Copy of Master degree or equivalent degree in medicine or natural sciences or any other study programme covering the same contents
The above document should be submitted as a certified English translation
Copy of transcript of records of the examinations taken during the Master degree programme
The above document should be submitted as a certified English translation
If the point above is not applicable, record of all study achievements and examination results obtained in the course of studies until the application deadline
Employment verification/reference letters accounting for professional experience in oncology
Personal statement, which explains why you believe you are eligible for this programme and how and why it will further support your intended career
Supporting documents to verify additional qualifications

Attendance

To obtain the Certificate of Advanced Studies in Lung Cancer, a participant has earned at least 14 ECTS credits. Active participation is required.

Eligibility

The programme is designed for medical doctors (medical oncology, radiation oncology, thoracic surgery, radiology, nuclear medicine, pathology), but it is equally accessible to graduates in natural sciences, who are engaged in the field of oncology, especially in the field of thoracic malignancies.

Medical Doctors:
Master degree from an accredited college or university [1] in medicine or an equivalent degree at the level of state examination in medicine and have had at least two years' residency training in a relevant institution.

Natural Scientists:
Master Degree from an accredited college or university in a course of studies in natural sciences or an equivalent degree at the level of at least three years of studies or in a course of studies with essentially the same contents [2] at an accredited college or university and at least two years of professional experience in oncology.

 

The following additional achievements will increase the assessment rate of the application:

 

  • Further professional experience related to the course of studies
  • Completion of an additional qualification in oncology (specialist training as a physician or international equivalent, e.g., board certified oncologist)
  • Publications, as evidenced by cumulative impact factors greater than 10
  • At least one year of relevant oncological experience in a foreign country

(1) e.g. State examination in medicine
(2) Examples of courses of study with essentially the same contents are biology, molecular medicine, biochemistry and pharmacology (state examination)

 

Application



This programme takes place every two years and the 2021/2022 edition of this programme is already underway.

The next cohort will take place from 2023/2024, with applications opening in summer 2022.

 

Tuitition Fee

The tuition fee is EUR 5,400.  A discounted fee of EUR 3,000 is implemented and made available to participants from low, lower middle and upper middle-income economies as defined by The World Bank.

The tuition fee includes access to seminars, modules, materials and exams as foreseen by the programme as well as accommodation, lunches and coffee breaks during the seminars.  The tuition fee does not include travel to the seminars.

The fee will be payable to the University of Zurich in two deposits representing the 50% of the total fee.

 

Editorial Board

Chairs

  • Alessandra Curioni, University Hospital Zurich, Switzerland
  • Enriqueta Felip, Vall d'Hebron University Hospital, Barcelona, Spain
  • Matthias Guckenberger, University Hospital, Zurich, Switzerland
  • Rolf A. Stahel, University Hospital, Zurich, Switzerland

Module Scientific Directors

Module 1:

  • Keith Kerr, UMS Aberdeen, UK
  • Lukas Bubendorf, University Hospital Basel, Switzerland

Module 2:

  • Christian Britschgi, University Hospital Zurich, Switzerland
  • Solange Peters, CHUV Lausanne, Switzerland


Module 3:

  • Isabelle Schmitt-Opitz, University Hospital Zurich, Switzerland
  • Suresh Senan, VU Amsterdam, The Netherlands


Module 4:

  • Alessandra Curioni, University Hospital Zurich, Switzerland
  • Martin Früh, St. Gallen Cantonal Hospital, Switzerland

Conceptual Development and Organisation

  • Moira Marzo, University Hospital Zurich, Switzerland
  • Alexandra Zampetti, ESO Bellinzona, Switzerland